Research
Hormonal
A prolonged lapse in GLP-1 receptor agonist therapy warrants consideration of reinitiation at a reduced dose.
Practitioners should consider starting patients on a reduced dose after a significant therapy lapse.
StrongSupportsmedium confidence
A prolonged lapse in GLP-1 receptor agonist therapy, typically defined as missing three or more doses of a once-weekly injectable, warrants consideration of reinitiation at a reduced dose.
Why this rating
The case report provides a detailed account of an adverse drug event related to therapy reinitiation.
Source
Navigating Glucagon-Like Peptide Receptor Agonist Reinitiation Amid Access Barriers: An Adverse Drug Event Case Report
Olivia Denny et al. · Journal of Pharmacy Practice · 2024
case_studyCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →